Cargando…
Capacity building in screening and treatment of diabetic retinopathy in Asia-Pacific region
The focus of capacity building for screening and treatment of diabetic retinopathy (DR) is on health professionals who are nonophthalmologists. Both physicians and nonphysicians are recruited for screening DR. Although there is no standardization of the course syllabus for the capacity building, it...
Autores principales: | , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Wolters Kluwer - Medknow
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8725108/ https://www.ncbi.nlm.nih.gov/pubmed/34708730 http://dx.doi.org/10.4103/ijo.IJO_1075_21 |
_version_ | 1784626046670209024 |
---|---|
author | Silpa-archa, Sukhum Limwattanayingyong, Jirawut Tadarati, Mongkol Amphornphruet, Atchara Ruamviboonsuk, Paisan |
author_facet | Silpa-archa, Sukhum Limwattanayingyong, Jirawut Tadarati, Mongkol Amphornphruet, Atchara Ruamviboonsuk, Paisan |
author_sort | Silpa-archa, Sukhum |
collection | PubMed |
description | The focus of capacity building for screening and treatment of diabetic retinopathy (DR) is on health professionals who are nonophthalmologists. Both physicians and nonphysicians are recruited for screening DR. Although there is no standardization of the course syllabus for the capacity building, it is generally accepted to keep their sensitivity >80%, specificity >95%, and clinical failure rate <5% for the nonophthalmologists, if possible. A systematic literature search was performed using the PubMed database and the following search terms: diabetic retinopathy, diabetic retinopathy screening, Asia, diabetic retinopathy treatment, age-related macular degeneration, capacity building, deep learning, artificial intelligence (AI), nurse-led clinic, and intravitreal injection (IVI). AI may be a tool for improving their capacity. Capacity building on IVIs of antivascular endothelial growth factors for DR is focused on nurses. There is evidence that, after a supervision of an average of 100 initial injections, the trained nurses can do the injections effectively and safely, the rate of endophthalmitis ranges from 0.03 to 0.07%, comparable to ophthalmologists. However, laws and regulations, which are different among countries, are challenges and barriers for nonophthalmologists, particularly for nonphysicians, for both screening and treatment of DR. Even if nonphysicians or physicians who are nonophthalmologists are legally approved for these tasks, sustainability of the capacity is another important challenge, this may be achieved if the capacity building can be part of their career development. Patient acceptability is another important barrier for initiating care provided by nonophthalmologists, particularly in Asia. There are also collaborations between national eye institutes of high-income countries, nongovernment organizations, and local eye institutes to improve both the quality and quantity of ophthalmologists and retinal specialists in low-income countries in Asia. This approach may require more labor, cost, and time consuming than training nonophthalmologists. |
format | Online Article Text |
id | pubmed-8725108 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | Wolters Kluwer - Medknow |
record_format | MEDLINE/PubMed |
spelling | pubmed-87251082022-01-20 Capacity building in screening and treatment of diabetic retinopathy in Asia-Pacific region Silpa-archa, Sukhum Limwattanayingyong, Jirawut Tadarati, Mongkol Amphornphruet, Atchara Ruamviboonsuk, Paisan Indian J Ophthalmol Review Article The focus of capacity building for screening and treatment of diabetic retinopathy (DR) is on health professionals who are nonophthalmologists. Both physicians and nonphysicians are recruited for screening DR. Although there is no standardization of the course syllabus for the capacity building, it is generally accepted to keep their sensitivity >80%, specificity >95%, and clinical failure rate <5% for the nonophthalmologists, if possible. A systematic literature search was performed using the PubMed database and the following search terms: diabetic retinopathy, diabetic retinopathy screening, Asia, diabetic retinopathy treatment, age-related macular degeneration, capacity building, deep learning, artificial intelligence (AI), nurse-led clinic, and intravitreal injection (IVI). AI may be a tool for improving their capacity. Capacity building on IVIs of antivascular endothelial growth factors for DR is focused on nurses. There is evidence that, after a supervision of an average of 100 initial injections, the trained nurses can do the injections effectively and safely, the rate of endophthalmitis ranges from 0.03 to 0.07%, comparable to ophthalmologists. However, laws and regulations, which are different among countries, are challenges and barriers for nonophthalmologists, particularly for nonphysicians, for both screening and treatment of DR. Even if nonphysicians or physicians who are nonophthalmologists are legally approved for these tasks, sustainability of the capacity is another important challenge, this may be achieved if the capacity building can be part of their career development. Patient acceptability is another important barrier for initiating care provided by nonophthalmologists, particularly in Asia. There are also collaborations between national eye institutes of high-income countries, nongovernment organizations, and local eye institutes to improve both the quality and quantity of ophthalmologists and retinal specialists in low-income countries in Asia. This approach may require more labor, cost, and time consuming than training nonophthalmologists. Wolters Kluwer - Medknow 2021-11 2021-10-29 /pmc/articles/PMC8725108/ /pubmed/34708730 http://dx.doi.org/10.4103/ijo.IJO_1075_21 Text en Copyright: © 2021 Indian Journal of Ophthalmology https://creativecommons.org/licenses/by-nc-sa/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution-Noncommercial-Share Alike 4.0 Unported, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | Review Article Silpa-archa, Sukhum Limwattanayingyong, Jirawut Tadarati, Mongkol Amphornphruet, Atchara Ruamviboonsuk, Paisan Capacity building in screening and treatment of diabetic retinopathy in Asia-Pacific region |
title | Capacity building in screening and treatment of diabetic retinopathy in Asia-Pacific region |
title_full | Capacity building in screening and treatment of diabetic retinopathy in Asia-Pacific region |
title_fullStr | Capacity building in screening and treatment of diabetic retinopathy in Asia-Pacific region |
title_full_unstemmed | Capacity building in screening and treatment of diabetic retinopathy in Asia-Pacific region |
title_short | Capacity building in screening and treatment of diabetic retinopathy in Asia-Pacific region |
title_sort | capacity building in screening and treatment of diabetic retinopathy in asia-pacific region |
topic | Review Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8725108/ https://www.ncbi.nlm.nih.gov/pubmed/34708730 http://dx.doi.org/10.4103/ijo.IJO_1075_21 |
work_keys_str_mv | AT silpaarchasukhum capacitybuildinginscreeningandtreatmentofdiabeticretinopathyinasiapacificregion AT limwattanayingyongjirawut capacitybuildinginscreeningandtreatmentofdiabeticretinopathyinasiapacificregion AT tadaratimongkol capacitybuildinginscreeningandtreatmentofdiabeticretinopathyinasiapacificregion AT amphornphruetatchara capacitybuildinginscreeningandtreatmentofdiabeticretinopathyinasiapacificregion AT ruamviboonsukpaisan capacitybuildinginscreeningandtreatmentofdiabeticretinopathyinasiapacificregion |